Events

January 13th, 2025 – Monheim, Germany

Cube Biotech and IBA Lifesciences, two leading innovators in the biotechnology industry, join forces to create a unified powerhouse dedicated to advancing research and production capabilities for the life science industry. 

The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization, and to enable groundbreaking research in the field of challenging drug targets.  Cube Biotech's vision to accelerate innovation, simplify services, and broaden its global presence is reflected in the acquisition. Over the course of the last 12 months, the company has formed multiple collaborations to realize these goals.

By combining Cube Biotech’s expertise in protein technologies with IBA Lifesciences strength in high performance research tools for protein isolation and analysis, the new entity is uniquely positioned to address the evolving needs of researchers and industry professionals worldwide. 

 Strategic Highlights of the Acquisition:  

Enhanced Product Portfolio: Integration of Cube Biotech’s portfolio of stabilized membrane proteins via its NativeMP® platform and purification resins with IBA Lifesciences’ proprietary Strep-tag® affinity technology.  

Global Reach: Expanding distribution channels and operational capabilities to better serve customers in North America, Europe, and Asia.

Innovative R&D Synergy: Combining research and development teams to drive groundbreaking advancements in life science research and the drug discovery value chain. 

Customer-Centric Solutions: Focus on delivering comprehensive, customizable solutions tailored to the specific needs of pharmaceutical, biotech and academic customers.  

Didier Dargent, CEO of Cube Biotech, stated, “This acquisition marks an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.” 

Mike Rothe, CEO of IBA Lifesciences, added, “The fusion of our technologies and talents creates an outstanding foundation for innovation. Our combined efforts will benefit our customers and strengthen our position as leaders in the biotechnology market.”  

About Cube Biotech GmbH – www.cube-biotech.com - Headquartered in Monheim, Germany, Cube Biotech is a leading provider of solutions for protein purification, stabilization, and structural studies. Known for its high-quality purification resins and membrane protein stabilization kits, Cube Biotech serves researchers across academia and industry. Cube Biotech is an ARCHIMED company since 2021.  

About ARCHIMED – www.archimed.group - With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. 

About IBA Lifesciences GmbH – www.iba-lifesciences.com - Based in Göttingen, Germany, IBA Lifesciences is renowned for its pioneering Strep-tag® system and innovative solutions in protein applications. With a strong focus on high-quality tools for biomolecular research, IBA Lifesciences has earned a global reputation for excellence.  

For more information about the acquisition or to speak with a representative, please contact:

Press Inquiries: 

Michael Ries 

Head of Sales and Marketing, Cube Biotech

Email: michael.ries@cube-biotech.com

[Göttingen, 02.04.2024] — IBA Lifesciences is thrilled to announce the promotion of Fabian Mohr, Ph.D, from Vice President of Research and Development (R&D) to Chief Scientific Officer (CSO), effective immediately. This strategic move is a testament to Fabian Mohr's exceptional contributions to the company and his proven leadership in driving innovation.

Fabian Mohr brings to his new role a rich background in biological research and a passionate commitment to advancing the field of biotechnology. He earned his master’s degree in biology from the Technical University of Munich, where he delved into research that laid the foundation for his future endeavors. During his PhD thesis, Fabian Mohr worked in the field of immunotherapy, focusing on the isolation of minimally manipulated regulatory T cells for adoptive T cell therapy.

Joining IBA Lifesciences in 2019, Fabian Mohr quickly established himself as a leader in his role as Vice President of R&D. He has played a key role in driving product and technology innovation, effectively leading projects and encouraging a culture of creativity in the R&D department.

In his new role as Chief Scientific Officer, Fabian Mohr will oversee the company's scientific strategy, ensuring that IBA Lifesciences remains competitive in developing solutions that meet the changing demands of the biotech market. His leadership will be important in directing the company's research initiatives and product strategy.

"In this role, I am confident that our commitment to excellence and innovation will guide us to new heights. The foundation of our success lies in the excellence of our products, and I am committed to nurturing that foundation through collaborative innovation, further enhancing and refining the Strep-tag® technology." - Fabian Mohr, Ph.D, newly appointed Chief Scientific Officer at IBA Lifesciences.

"We believe that with Fabian at the helm of our scientific strategy, our research efforts will be well-positioned for success," said Dr. Mike Rothe, CEO of IBA Lifesciences. "His extensive knowledge, creative approach, and dedication to high standards make him a strong fit to lead our scientific endeavors."

**About IBA Lifesciences**

IBA Lifesciences GmbH is a biotechnology company that develops innovative products for life science research in both academic and industrial settings. Our unique Strep-tag® technology opens up a wide range of application possibilities in the purification and analysis of recombinant proteins. Headquartered in Göttingen, our products are distributed through a global network of distributors, reaching over 40 countries across 5 continents.

For further information: https://www.iba-lifesciences.com/

Press contact:
Anna Färger 
Director Marketing / PR
IBA Lifesciences GmbH 
Rudolf-Wissell-Str. 28, 
37079 Goettingen, Germany 
 +49 (0)551 50672-0 
info@iba-lifesciences.com
www.iba-lifesciences.com

IBA Lifesciences and Gator Bio collaborated on the newly launched Strep-Tactin®XT probes - ready-to-use Strep-Tactin®XT-covered biosensors for BLI (Biolayer Interferometry). They allow capturing and subsequent quantitation and kinetic analysis of Twin-Strep-tag® fusion proteins.

Gator Bio is offering the whole range of products as devices, software and consumables for Biolayer Interferometry analysis - a label-free, real-time measurement of biomolecules.

Strep-Tactin®XT is an engineered streptavidin and part of IBA Lifesciences’ 3rd generation versatile Strep-tag® system. It exhibits strong (pM range), but reversible binding to the Twin-Strep-tag® peptide, allowing all kinds of protein analytic applications.

The corresponding application note is planned for early autumn 2023. The product is already available for order .

IBA Lifesciences and IMCS collaborated for the development of new product, which combines Strep-Tactin®XT with the IMCStips® allowing an automated, fast, and efficient purification of Strep-tagged proteins. IMCS provides with its IMCStips® a dispersive pipette extraction technology which streamlines the protein and peptide sample preparation process through automation. It can be applied across many different automation platforms and ALH devices.

Combined with IBA’s unique Strep-tag®:Strep-Tactin®-system, which is one of the most widely used systems for affinity protein purification, the IMCStips® XT HC allows a fast, efficient and autonomous way to purify Strep-tagged proteins. The corresponding application note by IMCS provides additional information and insights into the technology and its’ benefits with the focus on optimizing binding capacity and elution parameters.

For more information please feel free to contact us at: strep-tag@iba-lifesciences.com

Our powerful resins, Strep-Tactin®XT 4Flow® and Strep-Tactin®XT 4Flow® high capacity, replace Strep-Tactin®XT Superflow® as well as Strep-Tactin®XT Superflow® high capacity as of July 1st, 2021. In comparison to Strep-Tactin®XT Superflow® resins, Strep-Tactin®XT 4Flow® resins have improved and enhanced properties and are, therefore, our Strep-Tactin®XT resins for the future.

Strep-Tactin®XT 4Flow® and the high capacity variant are perfectly suitable for efficient protein purification independent from the protein class, including challenging proteins, low abundant proteins and especially large proteins. Furthermore, the broad pH stability enhanced the compatibility with different buffer compositions.

The new structure organizes IBA Lifesciences’ core business operations around two strategic departments: Protein Production & Assays and Cell Selection & Expansion. These product lines are united by IBAs’ proprietary and versatile platform, the Strep-tag® technology.

As part of this process, IBA will discontinue the production of custom oligonucleotides. All employees of the Custom Oligo & Predefined DNA/RNA department will be merged into the remaining two departments. As a result, this will strengthen the production as well as research and development of the protein production and cell selection tools.

The Custom Oligos & Predefined DNA/RNA department has served IBAs’ customers with specialized nucleic acid products and oligonucleotides since 1998. The company is extremely proud of all the accomplishments of the department in those years. Existing orders will be honored and IBA is working hard to ensure a timely delivery of the products.

Mike Rothe, IBA’s CEO said, “Focusing on our core technology will help us expand into promising new product areas, such as the field of exosome isolation. This is a key step in our strategic, long-term plan to better meet the demands of our globally expanding businesses, especially in Asia. The current re-allocation of resources will enable us to respond very quickly to the increasing demand of protein production and cell selection tools. This will result in major changes in efficiencies and position us well for future success.”

The company will begin to implement the restructuring immediately, and the reorganization is expected to be completed by September 2020.

About IBA Lifesciences

Founded in 1996, IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. IBA’s portfolio includes tools for cell selection and expansion as well as protein production and assays.

Contact details

Anna Färger

Director Marketing / PR

IBA Lifesciences GmbH

Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany

+49 (0)551 50672-0

info@iba-lifesciences.com

www.iba-lifesciences.com